MarketInOut Stock Screener Log In | Sign Up
 

Estrella Immunopharma Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/02/2026 16:00
Estrella Immunopharma Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization20.01 mln
Float17.42 mln
Earnings Date11/12/2026

Piotroski F-Score

3 / 9
Below average

Relative Strength

11 / 100
Significantly lagging

ROE

122
Extraordinary

ROA

-330
Deeply negative

Business Description

Estrella Immunopharma is a US-based medical company focused on developing T-cell treatments for patients with blood cancers and other tumors. Its pipeline includes three candidates ? EB103, EB104, and EB201 ? targeting conditions such as large B-cell lymphoma, acute lymphocytic leukemia, and lupus, at various stages of clinical testing. The company operates its own cell receptor platform, called ARTEMIS, and works alongside Eureka Therapeutics and Imugene Limited to advance combination therapies for solid tumors. Founded in 2006 and based in Emeryville, California, Estrella operates as a subsidiary of Eureka Therapeutics.

Key Fundamentals

EPS-0.25
ROE122
ROIC-606
ROA-330
EBITDA, mln-9.79
EV / EBITDA-3.12
EV / EBIT-3.12

Quote Details

Last 0.468
Change -0.007 (-1.47%)
Open 0.461
Volume 14,485
Turnover 6,778.98
Average Volume 42,396

Financial Strength

Piotroski F-Score 3 / 9
Short Ratio4.23
Short % of Float0.88

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -2.7% 27 / 100   
1 Month -32.17% 5 / 100   
2 Months -52.38% 6 / 100   
6 Months -55.43% 7 / 100   
1 Year -65.07% 12 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us